Laura Barker

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Richard T. Penson, Ricardo Villalobos-Valencia, David Cibula et al. · Journal of Clinical Oncology · 2020 · 295 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

James Glasbey, Adesoji Ademuyiwa, Adewale Adisa et al. · The Lancet Oncology · 2021 · 289 citations · Full text

Medicine, Oncology, Surgery +11

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad, Noel W. Clarke, Mototsugu Oya et al. · The Lancet Oncology · 2023 · 288 citations · Full text

Medicine, Oncology, Pharmacology +16

Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study

Christina Fotopoulou, Tabassum Khan, Juraj Bracinik et al. · American Journal of Obstetrics and Gynecology · 2022 · 61 citations · Full text

Medicine, Oncology, Surgery +6

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · Journal of Clinical Oncology · 2023 · 53 citations

Medicine, Oncology, Pharmacology +16